Multiple myeloma - lenalidomide: final appraisal determination (23rd April 2009)
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on lenalidomide for multiple myeloma in people who have received at least one prior therapy and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who, for this appraisal, have 20 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 15th May 2009.
FAD
After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on lenalidomide for multiple myeloma in people who have received at least one prior therapy and submitted it to the Institute. The FAD has been sent to the formal consultees for this appraisal who, for this appraisal, have 20 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales. Closing date for comments is 15th May 2009.
FAD
Extracorporeal shockwave therapy for refractory tennis elbow: interventional procedures consultation (25th April 2009)
NICE has reviewed the guidance on extracorporeal shockwave therapy for refractory tendinopathies (plantar fasciitis and tennis elbow) (IPG139, November 2005) and is reassessing the procedure separately for plantar fasciitis, tennis elbow (see below) and Achilles tendinopathy. New guidance will be published as a result. Until the new guidance is published the NHS should continue to follow the current recommendations.
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 may 2009).
Consultation
NICE has reviewed the guidance on extracorporeal shockwave therapy for refractory tendinopathies (plantar fasciitis and tennis elbow) (IPG139, November 2005) and is reassessing the procedure separately for plantar fasciitis, tennis elbow (see below) and Achilles tendinopathy. New guidance will be published as a result. Until the new guidance is published the NHS should continue to follow the current recommendations.
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 may 2009).
Consultation
Percutaneous intradiscal elecrothermal therapy for lower back pain: interventional procedures consultation (25th April 2009)
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 may 2009).
Consultation
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 may 2009).
Consultation
Extracorporeal shockwave therapy for refractory Achilles tendinopathy: interventional procedures consultation (25th April 2009)
NICE has reviewed the guidance on extracorporeal shockwave therapy for refractory tendinopathies (plantar fasciitis and tennis elbow) (IPG139, November 2005) and is reassessing the procedure separately for plantar fasciitis, tennis elbow and Achilles tendinopathy (see below). New guidance will be published as a result. Until the new guidance is published the NHS should continue to follow the current recommendations.
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 may 2009).
Consultation
NICE has reviewed the guidance on extracorporeal shockwave therapy for refractory tendinopathies (plantar fasciitis and tennis elbow) (IPG139, November 2005) and is reassessing the procedure separately for plantar fasciitis, tennis elbow and Achilles tendinopathy (see below). New guidance will be published as a result. Until the new guidance is published the NHS should continue to follow the current recommendations.
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 may 2009).
Consultation
Extracorporeal shockwave therapy for refractory plantar fasciitis: interventional procedures consultation (25th April 2009)
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on extracorporeal shock wave therapy for refractory tendinopathies (plantar fasciitis and tennis elbow) in November 2005.
NICE has reviewed the guidance on extracorporeal shockwave therapy for refractory tendinopathies (plantar fasciitis and tennis elbow) (IPG139, November 2005) and is reassessing the procedure separately for plantar fasciitis (see below), tennis elbow and Achilles tendinopathy. New guidance will be published as a result. Until the new guidance is published the NHS should continue to follow the current recommendations.
Consultation
The National Institute for Health and Clinical Excellence (NICE) has issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on extracorporeal shock wave therapy for refractory tendinopathies (plantar fasciitis and tennis elbow) in November 2005.
NICE has reviewed the guidance on extracorporeal shockwave therapy for refractory tendinopathies (plantar fasciitis and tennis elbow) (IPG139, November 2005) and is reassessing the procedure separately for plantar fasciitis (see below), tennis elbow and Achilles tendinopathy. New guidance will be published as a result. Until the new guidance is published the NHS should continue to follow the current recommendations.
Consultation
Placement of pectus bar for pectus excavatum (Nuss procedure) (25th April 2009)
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 May 2009).
Pectus excavatum is an abnormality of the chest in which the breastbone sinks inward (sometimes called funnel chest). Problems associated with pectus excavatum are mainly cosmetic, although the condition can impair cardiac and respiratory function. Placement of a pectus bar for pectus excavatum (also known as the Nuss procedure) involves placing one or two steel (pectus) bars under the breastbone with the aim of raising it and correcting the abnormal shape. The bar, which is bent into a curve to fit the patient’s chest, is inserted through small openings in the chest. The bar (or bars) are usually removed within a few years of placement.
Consultation
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 May 2009).
Pectus excavatum is an abnormality of the chest in which the breastbone sinks inward (sometimes called funnel chest). Problems associated with pectus excavatum are mainly cosmetic, although the condition can impair cardiac and respiratory function. Placement of a pectus bar for pectus excavatum (also known as the Nuss procedure) involves placing one or two steel (pectus) bars under the breastbone with the aim of raising it and correcting the abnormal shape. The bar, which is bent into a curve to fit the patient’s chest, is inserted through small openings in the chest. The bar (or bars) are usually removed within a few years of placement.
Consultation
Ultrasound-guided foam sclerotherapy for varicose veins: interventional procedures consultation (25th April 2009)
The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on ultrasound-guided foam sclerotherapy for varicose veins in May 2007. This replaced the previous guidance on 'Ultrasound guided foam sclerotherapy for varicose veins' (Interventional Procedures Guidance no. 182, June 2006).
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 may 2009).
Consultation
The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on ultrasound-guided foam sclerotherapy for varicose veins in May 2007. This replaced the previous guidance on 'Ultrasound guided foam sclerotherapy for varicose veins' (Interventional Procedures Guidance no. 182, June 2006).
The Interventional Procedures Advisory Committee has considered this procedure and NICE has now issued a consultation document about its safety and efficacy. This has been issued for 4 weeks public consultation (until 5pm on 26 may 2009).
Consultation
Eczema (chronic) - alitretinoin: appraisal consultation (30th April 2009)
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of alitretinoin for the treatment of severe chronic hand eczema and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted by the manufacturer and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of alitretinoin for the treatment of severe chronic hand eczema. Closing date for comments is 20th May 2009.
Consultation
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of alitretinoin for the treatment of severe chronic hand eczema and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted by the manufacturer and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of alitretinoin for the treatment of severe chronic hand eczema. Closing date for comments is 20th May 2009.
Consultation
School-based interventions to prevent smoking: consultation on the evidence (1st May 2009)
NICE was asked by the Department of Health (DH) to develop public health intervention guidance on School-based interventions to prevent the uptake of smoking amongst children. Closing date for comments is 3rd June 2009.
Consultation
NICE was asked by the Department of Health (DH) to develop public health intervention guidance on School-based interventions to prevent the uptake of smoking amongst children. Closing date for comments is 3rd June 2009.
Consultation
Reducing differences in uptake of immunisations: additional evidence consultation (5th May 2009)
NICE was asked by the Department of Health (DH) to develop public health intervention guidance to reduce differences in the uptake of immunisations (including targeted vaccines) in children and young people aged under 19 years. Closing date for comments is 2nd June 2009.
Consultation
Reducing differences in uptake of immunisations: draft guidance consultation (5th May 2009)
NICE is developing public health intervention guidance on differences in the uptake of immunisations (including targeted vaccines) in children and young people aged under 19 years. Closing date for comments is 2nd June 2009.
Consultation
NICE is developing public health intervention guidance on differences in the uptake of immunisations (including targeted vaccines) in children and young people aged under 19 years. Closing date for comments is 2nd June 2009.
Consultation
Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line): appraisal consultation (7th May 2009)
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of sorafenib for the treatment of hepatocellular carcinoma and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted by the manufacturer and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of sorafenib for the treatment of hepatocellular carcinoma. Closing date for comments is 29th May 2009.
Consultation
Prevention of cardiovascular disease: consultation on the evidence (12th May 2009)
NICE was asked by the Department of Health (DH) to develop guidance on the prevention of cardiovascular disease at the population level. Closing date for comments is 12th June 2009.
Consultation
The Department of Health has asked the National Institute for Health and Clinical Excellence (NICE or the Institute) to conduct a single technology appraisal (STA) of sorafenib for the treatment of hepatocellular carcinoma and provide guidance on its use to the NHS in England and Wales. The Appraisal Committee has had its first meeting to consider both the evidence submitted by the manufacturer and the views put forward by non-manufacturer consultees and commentators, and by the clinical specialist and patient expert representatives nominated for this appraisal by non-manufacturer consultees and commentators. The Committee has developed preliminary recommendations on the use of sorafenib for the treatment of hepatocellular carcinoma. Closing date for comments is 29th May 2009.
Consultation
Prevention of cardiovascular disease: consultation on the evidence (12th May 2009)
NICE was asked by the Department of Health (DH) to develop guidance on the prevention of cardiovascular disease at the population level. Closing date for comments is 12th June 2009.
Consultation
Latest Implementation Tools (13th May 2009)
Tools to aid implementation of recently published guidance
Diabetes type 2 (new drugs update): Costing tool
Diarrhoea and vomiting in children: Costing tool and Slide set
Glaucoma: Costing tool and Slide set
Breast cancer (advanced): Audit support and Guide to resources
Breast cancer (early): Audit support
Rheumatoid arthritis in adults: Audit support
Venous thromboembolism - rivaroxaban: Audit support and Costing tool
Needle and syringe programmes: Local authority planning committee checklist, Factsheet for commissioners and Audit support
Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency: Audit support
Ex-vivo hepatic resection and reimplantation for liver cancer: Audit support
Tools to aid implementation of recently published guidance
Diabetes type 2 (new drugs update): Costing tool
Diarrhoea and vomiting in children: Costing tool and Slide set
Glaucoma: Costing tool and Slide set
Breast cancer (advanced): Audit support and Guide to resources
Breast cancer (early): Audit support
Rheumatoid arthritis in adults: Audit support
Venous thromboembolism - rivaroxaban: Audit support and Costing tool
Needle and syringe programmes: Local authority planning committee checklist, Factsheet for commissioners and Audit support
Combined bony and soft tissue reconstruction for hip joint stabilisation in proximal focal femoral deficiency: Audit support
Ex-vivo hepatic resection and reimplantation for liver cancer: Audit support
No comments:
Post a Comment